Spero Therapeutics Inc Conference Call Transcript
Good morning, and welcome to the Spero Therapeutics Conference Call. (Operator Instructions) Please be advised that this call is being recorded and a replay will be available. You can find information on the replay and further information related to today's announcements on the Spero Therapeutics website at www.sperotherapeutics.com.
At this time, I would like to turn the call over to Ted Jenkins, Vice President, Investor Relations at Spero Therapeutics. Mr. Jenkins, please go ahead.
Thank you, operator, and thank you all for participating in today's conference call. Earlier this morning, Spero Therapeutics issued a news release announcing the new strategic direction it intends to take following feedback from our recent late cycle meeting with the FDA. This feedback suggests that the new drug application data package for Spero's Phase III ADAPT-PO study in complicated urinary tract infection may be insufficient to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |